… with or without T2D), respectively, with DAPA-CKD being the first trial to show a reduced risk
… A post hoc analysis of the RENAAL study found that each 50% reduction in albuminuria with …

… DAPA-CKD trial was discontinued by the data monitoring committee when an interim analysis
… Further trials with prespecified analysis would be required to establish this finding fully. …

… The analyses of the DAPASALT study were pre-specified and the analyses of the DIAMOND
… In summary, SGLT2 inhibitor dapagliflozin decreased blood pressure despite no clear …

… In conclusion, the pre-specified analysis of the DAPA-CKD trial has confirmed that … of an
abrupt decline in kidney function in patients with CKD. Although further studies are needed to …

… studies (CREDENCE, DAPA and EMPA CKD, the latter of … analysis of DAPA-CKD showed
no significant interaction of treatment effects (including efficacy and safety outcomes) by CKD …

… In addition, the DAPA-CKD study did not adopt 24 h … hence we considered this population
in DAPA-CKD to be eligible for … A pre-specified analysis of the DAPA-CKD trial demonstrates …

… The DAPA-CKD subgroup analysis included a group of patients with IgA nephropathy
and another with focal segmental glomerulosclerosis (FSGS). There were 270 subjects with …

… therapy) and the pre-specified secondary endpoints of total … summary score (OSS) and
clinical summary score (CSS). … In this post-hoc analysis of DAPA-HF we found that anaemia …

… In the pre-specified renal outcome analysis, the benazepril-amlodipine group was shown
to have a slower decrease in eGFR rate (−0.88 vs −4.22 mL/min/1.73m 2 per year) although it …

… a pre-specified … in DAPA-HF [11, 27] (2-year meta-number needed to treat of 21) and
EMPEROR-REDUCED [12, 27] (2-year meta-number needed to treat of 15), the present analysis …